person · Reporting owner
Dallas Jayson Donald Alexander
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | EVP & Chief Commercial Officer | June 01, 2018 | June 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 720 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 720 · Balance 720 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Ultragenyx Pharmaceutical Inc.
Report date June 01, 2018 · Filed June 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,830 |
Reported balance
After 2018-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-01 · Tax withholding · Disposed 294 · Balance 23,830 F1: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3: Includes 520 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: Includes 520 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 4,085 · Balance 3,067 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 3,067 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 4,167 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.17 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Aimmune Therapeutics, Inc.
Report date October 10, 2020 · Filed October 14, 2020
Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-10-10 · Other · Disposed 30,422 · Balance 0 F1: Includes 2,638 shares acquired pursuant to the Issuer's employee stock purchase plan. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-10-13 · Disposition to issuer · Disposed 89,250 · Balance 0 F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.68 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-13 · Disposition to issuer · Disposed 350,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.72 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-13 · Disposition to issuer · Disposed 210,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.81 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-13 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,638 shares acquired pursuant to the Issuer's employee stock purchase plan.
F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jun 20, 2025 07:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 720 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000950170-25-088167 · ownership.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720 Underlying: Common Stock · 720 shares Expires 2035-06-18 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000950170-24-076182 · ownership.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 20, 2024, the date of the Issuer's 2024 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 17, 2023 Filed Jun 15, 2023 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-037284 · doc4.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-22-036931 · doc4.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 7,202 | Not disclosed Strike: $65.19 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 9 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,202 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $61.31 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 8 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $56.50 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 7 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $49.17 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 6 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 5 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 4,167 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 4 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Disposition to issuerStock Option (right to buy) · Derivative | 7,500 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · derivative · entry 3 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 3,067 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · nonDerivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| March 11, 2022 Filed Mar 11, 2022 16:22 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 4,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-22-005908 · wf-form4_164703370685042.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,067 F1 · kind: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. F1 · price: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Read SEC document |
| June 15, 2021 Filed Jun 15, 2021 17:27 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | SaleCommon Stock | 1,223 | $66.36 | $81,158.28 |
DisclosureSEC source: 0001628280-21-012284 · wf-form4_162379243656469.xml · nonDerivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,152 F2 · kind: The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:27 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 7,202 | $0.00 Strike: $65.19 | $0.00 |
DisclosureSEC source: 0001628280-21-012284 · wf-form4_162379243656469.xml · derivative · entry 3 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,202 Underlying: Common Stock · 7,202 shares Expires 2028-06-11 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 11, 2021 with the final installment vesting upon the earlier of the one-year anniversary of the grant date or the date of the next annual stockholders' meeting, and are exercisable once vested. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:27 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-012284 · wf-form4_162379243656469.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,375 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 11, 2022, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| May 26, 2021 Filed May 28, 2021 16:00 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $4.93 | $0.00 |
DisclosureSEC source: 0001209191-21-036508 · doc4.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:06 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | SaleCommon Stock | 1,327 | $80.50 | $106,823.50 |
DisclosureSEC source: 0001209191-21-004585 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,308 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 16:07 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | PurchaseCommon Stock | 5 | $69.31 | $346.55 |
DisclosureSEC source: 0001209191-20-063452 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 16:03 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | PurchaseCommon Stock | 5 | $66.25 | $331.24 |
DisclosureSEC source: 0001209191-20-062475 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,630 Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:47 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000899243-20-031922 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-11-18 F2 · shares: Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.exercise_date: Represents a pro-rated annual option grant to a non-employee director upon appointment to the Board of Directors of the Company. The shares subject to such option vest in twelve equal monthly installments, commencing on November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 16:47 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000899243-20-031922 · doc4.xml · derivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-11-18 F1 · derivative.exercise_date: The shares subject to such option vest in 36 equal monthly installments over three years from the date of vesting commencement of November 19, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 200,000 | $10.69 Strike: $23.81 | $2,138,000.00 |
DisclosureSEC source: 0000899243-20-028181 · doc4.xml · derivative · entry 5 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 210,000 | $10.78 Strike: $23.72 | $2,263,800.00 |
DisclosureSEC source: 0000899243-20-028181 · doc4.xml · derivative · entry 4 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 210,000 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 350,000 | $3.82 Strike: $30.68 | $1,337,000.00 |
DisclosureSEC source: 0000899243-20-028181 · doc4.xml · derivative · entry 3 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires not disclosed F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerCommon Stock, $0.0001 par value | 89,250 | $34.50 | $3,079,125.00 |
DisclosureSEC source: 0000899243-20-028181 · doc4.xml · nonDerivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document |
| October 10, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | OtherCommon Stock, $0.0001 par value | 30,422 | $34.50 | $1,049,559.00 |
DisclosureSEC source: 0000899243-20-028181 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 2,638 shares acquired pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 17:17 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Tax withholdingCommon Stock, $0.0001 par value | 1,642 | $34.25 | $56,238.50 |
DisclosureSEC source: 0000899243-20-025345 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,034 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 33,000 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes the balance of 35,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes the balance of 60,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 22, 2020 Filed Jun 26, 2020 17:06 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Tax withholdingCommon Stock, $0.0001 par value | 7,907 | $18.02 | $142,484.14 |
DisclosureSEC source: 0000899243-20-017779 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,676 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 3,300 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F3 · balance_after: Includes 33,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes the balance of 35,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F5 · balance_after: Includes the balance of 60,000 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.31 | $0.00 |
DisclosureSEC source: 0001209191-20-037102 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-12 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 12, 2020, and are exercisable once vested. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037102 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,625 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 12, 2021, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. Read SEC document |
| May 10, 2020 Filed May 12, 2020 17:25 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012860 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,583 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F2 · balance_after: Includes 33,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 60,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 20:48 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | PurchaseCommon Stock, $0.0001 par value | 2,665 | $18.74 | $49,934.11 |
DisclosureSEC source: 0000899243-20-007815 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,283 F1 · balance_after: Includes 33,000 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 60,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:42 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Tax withholdingCommon Stock, $0.0001 par value | 3,081 | $23.81 | $73,358.61 |
DisclosureSEC source: 0000899243-20-007103 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,618 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 33,000 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F4 · balance_after: Includes 60,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 20:37 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.81 | $0.00 |
DisclosureSEC source: 0000899243-20-006853 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-28 F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 20:37 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006853 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,699 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 60,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 19, 2019 Filed Feb 14, 2020 17:23 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Tax withholdingCommon Stock, $0.0001 par value | 7,951 | $20.20 | $160,610.20 |
DisclosureSEC source: 0000899243-20-004693 · doc5.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,699 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 52,049 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F3 · balance_after: Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 18:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | SaleCommon Stock | 170 | $56.51 | $9,606.39 |
DisclosureSEC source: 0001209191-19-037485 · doc4.xml · nonDerivative · entry 3 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,179 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $56.64, inclusive. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 18:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | SaleCommon Stock | 1,355 | $55.82 | $75,633.93 |
DisclosureSEC source: 0001209191-19-037485 · doc4.xml · nonDerivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,349 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.42 to $56.27, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $56.50 | $0.00 |
DisclosureSEC source: 0001209191-19-037485 · doc4.xml · derivative · entry 4 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-13 F5 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:38 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037485 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,704 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:05 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 210,000 | $0.00 Strike: $23.72 | $0.00 |
DisclosureSEC source: 0000899243-19-004861 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2029-02-22 F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:05 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-004861 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,650 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 60,000 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| November 19, 2018 Filed Nov 19, 2018 20:12 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | PurchaseCommon Stock, $0.0001 par value | 50 | $27.56 | $1,378.00 |
DisclosureSEC source: 0000899243-18-029386 · doc4.xml · nonDerivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,650 Read SEC document |
| November 19, 2018 Filed Nov 19, 2018 20:12 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | PurchaseCommon Stock, $0.0001 par value | 3,600 | $27.56 | $99,208.80 |
DisclosureSEC source: 0000899243-18-029386 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,600 Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 19:06 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $30.68 | $0.00 |
DisclosureSEC source: 0000899243-18-017243 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 19, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 19, 2018 Filed Jun 19, 2018 19:06 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017243 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:29 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $49.17 | $0.00 |
DisclosureSEC source: 0001209191-18-038061 · doc4.xml · derivative · entry 2 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2018, and are exercisable once vested. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:29 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038061 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:50 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 294 | $73.73 | $21,676.62 |
DisclosureSEC source: 0001209191-18-035180 · doc4.xml · nonDerivative · entry 1 Dallas Jayson Donald Alexander · CIK 0001650322 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,830 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 520 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.